Research Article
Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors
Table. 1
Demographic and clinicopathologic characteristics of patients.
| | Characteristics | |
| | Median age of patients, years (range) | 56 (35-77) | | ≤60, (%) | 16 (64%) | | >60, (%) | 9 (36%) | | Gender, (%) | | | Male | 11 (44%) | | Female | 14 (56%) | | ECOG performance status, (%) | | | 0-1 | 9 (36%) | | ≥2 | 16 (64%) | | Tumor type | | | Lung cancer | 16 (64%) | | Gastric cancer | 6 (24%) | | Colorectal cancer | 2 (8%) | | Cholangiocarcinoma | 1 (4%) | | Line of pyrotinib treatment, (%) | | | 1 | 2 (8%) | | 2 | 9 (36%) | | 3 | 3 (12%) | | 4 | 5 (20%) | | ≥5 | 6 (24%) | | Median (range) | 3 (1-9) | | Pyrotinib treatment regimen, (%) | | | Pyrotinib | 18 (72%) | | Pyrotinib + trastuzumab | 2 (8%) | | Pyrotinib + L-OHP | 1 (4%) | | Pyrotinib + fruquintinib | 1 (4%) | | Pyrotinib+ anlotinib + pembrolizumab | 1 (4%) | | Pyrotinib+ nab-paclitaxel + trastuzumab | 1 (4%) | | Pyrotinib + camrelizumab | 1 (4%) | | HER-2 status type, (%) | | | IHC3+ | 7 (28%) | | FISH+ | 2 (8%) | | Amplification | 1 (4%) | | exon20 insertion mutations | 12 (48%) | | exon20 p.Tyr772-Ala775dup | 2 (8%) | | p.D769Y | 1 (4%) | | Starting dosage of pyrotinib, (%) | | | 400 mg | 17(68%) | | 320 mg | 6 (24%) | | 240 mg | 2 (8%) |
|
|
